Pre-made Sacituzumab benchmark antibody ( Whole mAb ADC, anti-TACSTD2 therapeutic antibody, Anti-EGP-1/EGP1/GA733-1/GA7331/GP50/M1S1/TROP2 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Sacituzumab biosimilar, Whole mAb ADC, Anti-TACSTD2 Antibody: Anti-EGP-1/EGP1/GA733-1/GA7331/GP50/M1S1/TROP2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Sacituzumab govitecan-hziy injection is used to treat triple-negative breast cancer that has spread (metastatic) or cannot be removed by surgery (unresectable locally advanced). It is given to patients who have received 2 or more cancer treatments, including at least 1 treatment for metastatic disease.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-503-1mg	1mg	Inquiry
GMP-Bios-ab-503-10mg	10mg	Inquiry
GMP-Bios-ab-503-100mg	100mg	Inquiry
GMP-Bios-ab-503-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Sacituzumab biosimilar, Whole mAb ADC, Anti-TACSTD2 Antibody: Anti-EGP-1/EGP1/GA733-1/GA7331/GP50/M1S1/TROP2 therapeutic antibody
INN Name	Sacituzumab
Target	TACSTD2
Format	Whole mAb ADC
Derivation	Humanized
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Approved
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2016
Year Recommended	2017
Companies	IBC Pharmaceuticals;Immunomedics;University of Wisconsin Comprehensive Cancer Center;Yale University
Conditions Approved	Breast cancer
Conditions Active	Prostate cancer;Solid tumours;Urogenital cancer;Endometrial cancer;Glioblastoma
Conditions Discontinued	na
Development Tech	na